Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay

J Neurovirol. 2016 Dec;22(6):880-881. doi: 10.1007/s13365-016-0482-z. Epub 2016 Oct 11.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral / analysis*
  • Data Interpretation, Statistical
  • Humans
  • Immunologic Factors / adverse effects*
  • Incidence
  • JC Virus
  • Leukoencephalopathy, Progressive Multifocal / chemically induced*
  • Leukoencephalopathy, Progressive Multifocal / epidemiology*
  • Natalizumab / adverse effects*
  • Risk Factors

Substances

  • Antibodies, Viral
  • Immunologic Factors
  • Natalizumab